Anika Therapeutics (ANIK) FCF Margin (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of FCF Margin data on file, last reported at 16.55% in Q1 2026.

• On a quarterly basis, FCF Margin fell 1414.0% year-over-year to 16.55% in Q1 2026; TTM through Mar 2026 was 0.08%, a 409.0% decrease from a year earlier, with the FY2025 full-year figure at 3.87%, down 11.0% from the prior year.
• FCF Margin for Q1 2026 stood at 16.55%, down from 7.03% in the prior quarter.
• Over the last five years, FCF Margin for ANIK reached as high as 247.47% in Q4 2022 and fell as low as 62.02% in Q4 2023.
• Historically, FCF Margin has averaged 11.12% across 5 years, with a median of 2.58% in 2024.
• Across the five-year window, FCF Margin surged 23813 bps in 2022 and plunged 30949 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 247.47% in 2022, then sank by 125 bps to 62.02% in 2023, then jumped by 106 bps to 3.47% in 2024, then sank by 303 bps to 7.03% in 2025, then plunged by 135 bps to 16.55% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 16.55% in Q1 2026, 7.03% in Q4 2025, and 39.99% in Q3 2025.